Overview Dividends

(CLB) Core Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: NL0000200384

Reservoir Description, Production Enhancement

Oil & Gas Equipment & Services
Market Cap in USD: 773m

IPO / Inception: 1995-09-20
Return 12m vs S&P 500: -16.5%

EPS (Earnings per Share)

EPS CAGR: 2.57%
EPS Trend: 44.5%

Last SUE: 2.12
Qual. Beats: 1

Revenue

Rev. CAGR: 1.95%
Rev. Trend: 66.9%

Last SUE: 1.05
Qual. Beats: 1

Dividends

Dividend Yield	0.25%
Yield on Cost 5y	0.16%
Yield CAGR 5y	-38.52%
Payout Consistency	84.6%
Payout Ratio	5.2%

Risk via 5d forecast
Volatility	44.9%
Value at Risk 5%th	68.4%
Relative Tail Risk	-7.38%

Reward TTM
Sharpe Ratio	0.06
Alpha	-34.71
CAGR/Max DD	-0.09

Character TTM
Hurst Exponent	0.472
Beta	1.540
Beta Downside	1.588

Drawdowns 3y
Max DD	64.29%
Mean DD	32.26%
Median DD	33.31%

Description: CLB Core Laboratories October 23, 2025

Core Laboratories Inc. (NYSE: CLB) delivers reservoir description and production-enhancement services to oil- and-gas operators worldwide, operating through two segments: Reservoir Description, which characterizes rock and fluid samples to boost recovery, and Production Enhancement, which supplies well-completion, stimulation, and diagnostic solutions for improved well performance and EOR projects.

Key performance indicators from recent filings show FY 2023 revenue of roughly $1.1 billion with an operating margin near 14 %, while the company’s cash flow remains sensitive to upstream capital-expenditure cycles and oil-price volatility-core economic drivers that can swing demand for its laboratory and field services.

Sector-wide, CLB benefits from rising upstream spending on enhanced-oil-recovery techniques and carbon-capture initiatives, both of which are accelerating as regulators tighten emissions standards and producers seek to extend field life; however, a prolonged downturn in drilling activity could compress service pricing and utilization rates.

For a deeper quantitative view of CLB’s valuation relative to peers, the ValueRay platform offers a concise, data-driven dashboard worth checking.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (32.1m TTM) > 0 and > 6% of Revenue (6% = 31.1m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -1.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 25.35% (prev 26.83%; Δ -1.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 50.5m > Net Income 32.1m (YES >=105%, WARN >=100%)

Net Debt (141.5m) to EBITDA (73.1m) ratio: 1.94 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (47.1m) change vs 12m ago -1.55% (target <= -2.0% for YES)

Gross Margin 17.12% (prev 18.30%; Δ -1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 86.84% (prev 87.07%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.17 (EBITDA TTM 73.1m / Interest Expense TTM 10.6m) >= 6 (WARN >= 3)

Altman Z'' 3.59

(A) 0.22 = (Total Current Assets 226.9m - Total Current Liabilities 95.7m) / Total Assets 591.4m

(B) 0.29 = Retained Earnings (Balance) 173.6m / Total Assets 591.4m

(D) 0.54 = Book Value of Equity 168.1m / Total Liabilities 314.0m

Total Rating: 3.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.25

1. Piotroski 5.0pt

2. FCF Yield 3.81%

3. FCF Margin 6.74%

4. Debt/Equity 0.62

5. Debt/Ebitda 1.94

6. ROIC - WACC (= 1.56)%

7. RoE 12.38%

8. Rev. Trend 66.86%

9. EPS Trend 44.47%

What is the price of CLB shares?

As of December 22, 2025, the stock is trading at USD 16.24 with a total of 1,065,417 shares traded.
Over the past week, the price has changed by -1.87%, over one month by +10.33%, over three months by +33.97% and over the past year by -3.27%.

Is CLB a buy, sell or hold?

Core Laboratories has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold CLB.

Strong Buy: 0
Buy: 1
Hold: 3
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the CLB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	14	-13.8%
Analysts Target Price	14	-13.8%
ValueRay Target Price	17.2	6.2%

CLB Fundamental Data Overview December 15, 2025

Market Cap USD = 772.8m (772.8m USD * 1.0 USD.USD)
P/E Trailing = 24.2353
P/E Forward = 19.7628
P/S = 1.4933
P/B = 2.828
P/EG = 1.6717
Beta = 1.087
Revenue TTM = 517.5m USD
EBIT TTM = 54.7m USD
EBITDA TTM = 73.1m USD
Long Term Debt = 114.1m USD (from longTermDebt, last quarter)
Short Term Debt = 11.5m USD (from shortTermDebt, last quarter)
Debt = 167.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 141.5m USD (from netDebt column, last quarter)
Enterprise Value = 914.3m USD (772.8m + Debt 167.1m - CCE 25.6m)
Interest Coverage Ratio = 5.17 (Ebit TTM 54.7m / Interest Expense TTM 10.6m)
FCF Yield = 3.81% (FCF TTM 34.9m / Enterprise Value 914.3m)
FCF Margin = 6.74% (FCF TTM 34.9m / Revenue TTM 517.5m)
Net Margin = 6.21% (Net Income TTM 32.1m / Revenue TTM 517.5m)
Gross Margin = 17.12% ((Revenue TTM 517.5m - Cost of Revenue TTM 428.9m) / Revenue TTM)
Gross Margin QoQ = 19.35% (prev 17.51%)
Tobins Q-Ratio = 1.55 (Enterprise Value 914.3m / Total Assets 591.4m)
Interest Expense / Debt = 1.59% (Interest Expense 2.65m / Debt 167.1m)
Taxrate = 20.54% (3.75m / 18.3m)
NOPAT = 43.5m (EBIT 54.7m * (1 - 20.54%))
Current Ratio = 2.37 (Total Current Assets 226.9m / Total Current Liabilities 95.7m)
Debt / Equity = 0.62 (Debt 167.1m / totalStockholderEquity, last quarter 271.3m)
Debt / EBITDA = 1.94 (Net Debt 141.5m / EBITDA 73.1m)
Debt / FCF = 4.06 (Net Debt 141.5m / FCF TTM 34.9m)
Total Stockholder Equity = 259.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.43% (Net Income 32.1m / Total Assets 591.4m)
RoE = 12.38% (Net Income TTM 32.1m / Total Stockholder Equity 259.5m)
RoCE = 14.65% (EBIT 54.7m / Capital Employed (Equity 259.5m + L.T.Debt 114.1m))
RoIC = 11.39% (NOPAT 43.5m / Invested Capital 381.8m)
WACC = 9.84% (E(772.8m)/V(939.9m) * Re(11.69%) + D(167.1m)/V(939.9m) * Rd(1.59%) * (1-Tc(0.21)))
Discount Rate = 11.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.50%
[DCF Debug] Terminal Value 70.50% ; FCFE base≈38.5m ; Y1≈47.5m ; Y5≈81.1m
Fair Price DCF = 16.84 (DCF Value 784.0m / Shares Outstanding 46.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 44.47 | EPS CAGR: 2.57% | SUE: 2.12 | # QB: 1
Revenue Correlation: 66.86 | Revenue CAGR: 1.95% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.75 | Chg30d=-0.083 | Revisions Net=-2 | Growth EPS=+1.6% | Growth Revenue=-0.8%

Additional Sources for CLB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle